Home>News & Events>Publications>C-Path>Towards Consensus Practices to Qualify Safety Biomarkers for Use in Early Drug Development
May 10, 2010 PRINT PDF
What Evidence Do We Need for Biomarker Qualification?
Preclinical Biomarker Qualification
Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories
Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats
Cross-Laboratory Analytical Validation of the Cardiac Biomarker NT-proANP in Rat